|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3750 AUD | +4.17% |
|
-1.32% | -42.31% |
| 21/07 | Recce Pharmaceuticals Reports Higher Cash Balance in June Quarter | MT |
| 20/07 | Recce Pharmaceuticals Extends Share Purchase Plan Closing Date | MT |
| Market Cap | 11Cr 7.85Cr 6.9Cr 6.43Cr 5.9Cr 11Cr 753.22Cr 76Cr 30Cr 371.93Cr 29Cr 29Cr 1.29TCr | P/E 2026 * |
-6.15x | P/E 2027 * | -4.41x |
|---|---|---|---|---|---|
| Enterprise Value | 12Cr 8.22Cr 7.23Cr 6.73Cr 6.18Cr 12Cr 788.33Cr 80Cr 31Cr 389.26Cr 31Cr 30Cr 1.35TCr | EV / Sales 2026 * |
15.1x | EV / Sales 2027 * | 11x |
| Free-Float |
60.61% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +4.17% | ||
| 1 week | -1.32% | ||
| Current month | -7.41% | ||
| 1 month | -6.25% | ||
| 3 months | -29.25% | ||
| 6 months | -43.18% | ||
| Current year | -42.31% |
| 1 week | 0.35 |  | 0.38 |
| 1 month | 0.35 | | 0.44 |
| Current year | 0.35 | | 0.73 |
| 1 year | 0.35 | | 0.73 |
| 3 years | 0.28 | | 0.76 |
| 5 years | 0.28 | | 1.38 |
| 10 years | 0.13 | | 1.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 28/08/2020 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Michele Dilizia
BRD | Director/Board Member | - | 01/10/2012 |
James Graham
BRD | Director/Board Member | - | 01/05/2012 |
| Director/Board Member | - | 01/09/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 24/02/26 | Expiration | Chief Executive Officer | 22,50,000 | 0.7781% | ||
| 14/10/25 | Expiration | Chief Executive Officer | 7,45,962 | 0.3217% | ||
| 21/11/24 | Buy | Chairman | 26,50,000 | 1.1429% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.17% | -1.32% | -15.73% | -46.81% | 7.54Cr | |
| +0.09% | +4.49% | +48.29% | +163.38% | 1,06700Cr | |
| +1.70% | +7.81% | +61.39% | +54.45% | 63TCr | |
| -0.23% | +2.25% | +37.43% | +74.06% | 46TCr | |
| +1.41% | +8.56% | +38.18% | +32.17% | 35TCr | |
| +1.28% | +4.40% | +37.69% | +41.62% | 30TCr | |
| +1.72% | +4.10% | +19.44% | +20.45% | 26TCr | |
| +1.84% | -0.46% | -27.63% | -38.65% | 22TCr | |
| +0.31% | +3.75% | +25.40% | +60.06% | 20TCr | |
| +1.73% | -1.22% | +16.41% | +71.98% | 16TCr | |
| Average | +1.53% | +0.67% | +24.09% | +43.27% | 36.44TCr | |
| Weighted average by Cap. | +0.96% | +1.95% | +38.13% | +78.76% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 77.79L 54.41L 47.83L 44.52L 40.89L 76.78L 52Cr 5.29Cr 2.07Cr 26Cr 2.04Cr 2Cr 89Cr | 1.25Cr 87.39L 76.83L 71.52L 65.68L 1.23Cr 84Cr 8.5Cr 3.32Cr 41Cr 3.28Cr 3.21Cr 143.04Cr |
| Net income | -1.83Cr -1.28Cr -1.12Cr -1.05Cr -96.15L -1.81Cr -122.69Cr -12Cr -4.86Cr -61Cr -4.8Cr -4.7Cr -209.39Cr | -2.51Cr -1.76Cr -1.54Cr -1.44Cr -1.32Cr -2.48Cr -168.34Cr -17Cr -6.67Cr -83Cr -6.59Cr -6.45Cr -287.3Cr |
| Net Debt | 52.35L 36.61L 32.19L 29.96L 27.52L 51.67L 35Cr 3.56Cr 1.39Cr 17Cr 1.37Cr 1.34Cr 60Cr | 2.5Cr 1.75Cr 1.53Cr 1.43Cr 1.31Cr 2.46Cr 167.43Cr 17Cr 6.63Cr 83Cr 6.55Cr 6.41Cr 285.76Cr |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 27/26/27 | A$0.3750 | +4.17% | 1,34,821 |
| 24/26/24 | A$0.3600 | 0.00% | 65,425 |
| 23/26/23 | A$0.3600 | +2.86% | 2,13,680 |
| 22/26/22 | A$0.3500 | -5.41% | 1,86,448 |
| 21/26/21 | A$0.3700 | +2.78% | 1,44,692 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
Select your edition
All financial news and data tailored to specific country editions
